Fate Therapeutics (FATE) Times Interest Earned (2013 - 2019)
Fate Therapeutics' (FATE) quarterly Times Interest Earned came in at -$0.28 in Q1 2026, up 10.9% YoY from -$0.26 in Q1 2025, and up 64.85% on a QoQ basis from -$0.81 in Q3 2025.
Powered by 
Analysis
Fate Therapeutics (FATE) Times Interest Earned (2013 - 2019) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Times Interest Earned data on file, last reported at -$0.28 in Q1 2026.
- Quarterly Times Interest Earned rose 10.9% year-over-year to -$0.28 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 (up 22.49% YoY) and the FY2025 annual result came in at -$0.38, up 34.45% from the prior year.
- Times Interest Earned rose to -$0.28 in Q1 2026, from -$0.81 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.15 in Q4 2023 to a low of -$4.65 in Q1 2022.
- A 5-year average of -$0.93 and a median of -$0.39 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned surged 90.7% — and 2025, when it sank 1068.8%.
- Tracing FATE's Times Interest Earned over 5 years: stood at -$0.22 in 2022, then surged by 31.76% to -$0.15 in 2023, then slipped by 14.92% to -$0.17 in 2024, then plunged by 372.22% to -$0.81 in 2025, then surged by 64.85% to -$0.28 in 2026.
- The last three Times Interest Earned figures came in at -$0.28 (Q1 2026), -$0.81 (Q3 2025), and -$3.39 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -49.62 |
| Sep 30, 2019 | -67.80 |
| Jun 30, 2019 | -58.89 |
| Mar 31, 2019 | -50.48 |
| Dec 31, 2018 | -38.57 |
| Sep 30, 2018 | -38.91 |
| Jun 30, 2018 | -46.13 |
| Mar 31, 2018 | -34.11 |
| Dec 31, 2017 | -29.72 |
| Sep 30, 2017 | -27.35 |
| Jun 30, 2017 | -45.14 |
| Mar 31, 2017 | -37.48 |
| Dec 31, 2016 | -23.26 |
| Sep 30, 2016 | -21.79 |
| Jun 30, 2016 | -18.40 |
| Mar 31, 2016 | -15.83 |
| Dec 31, 2015 | -13.29 |
| Sep 30, 2015 | -10.55 |
| Jun 30, 2015 | -12.03 |
| Mar 31, 2015 | -12.21 |